A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

December 19, 2019

Study Completion Date

January 27, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin icodec

Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.

DRUG

Insulin glargine U100

Participants will receive s.c. injections of insulin glargine OD for 16 weeks

Trial Locations (38)

14612

Novo Nordisk Investigational Site, Falkensee

20122

Novo Nordisk Investigational Site, Milan

20132

Novo Nordisk Investigational Site, Milan

22607

Novo Nordisk Investigational Site, Hamburg

23758

Novo Nordisk Investigational Site, Oldenburg I. Holst

24127

Novo Nordisk Investigational Site, Bergamo

30076

Novo Nordisk Investigational Site, Roswell

37203

Novo Nordisk Investigational Site, Nashville

37404

Novo Nordisk Investigational Site, Chattanooga

37411

Novo Nordisk Investigational Site, Chattanooga

48145

Novo Nordisk Investigational Site, Münster

66386

Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach

67059

Novo Nordisk Investigational Site, Ludwigshafen

75226

Novo Nordisk Investigational Site, Dallas

75230

Novo Nordisk Investigational Site, Dallas

75231

Novo Nordisk Investigational Site, Dallas

75301

Novo Nordisk Investigational Site, Hranice

76901

Novo Nordisk Investigational Site, Holešov

88100

Novo Nordisk Investigational Site, Catanzaro

89148

Novo Nordisk Investigational Site, Las Vegas

94598

Novo Nordisk Investigational Site, Walnut Creek

98057

Novo Nordisk Investigational Site, Renton

83404-7596

Novo Nordisk Investigational Site, Idaho Falls

03063

Novo Nordisk Investigational Site, Nashua

75390-9302

Novo Nordisk Investigational Site, Dallas

T6G 2E1

Novo Nordisk Investigational Site, Edmonton

V3Z 2N6

Novo Nordisk Investigational Site, Surrey

V5Y 3W2

Novo Nordisk Investigational Site, Vancouver

B3H 2Y9

Novo Nordisk Investigational Site, Halifax

L6S 0C6

Novo Nordisk Investigational Site, Brampton

L4K 4M2

Novo Nordisk Investigational Site, Concord

M9R 4E1

Novo Nordisk Investigational Site, Etobicoke

L8M 1K7

Novo Nordisk Investigational Site, Hamilton

L3P 7P2

Novo Nordisk Investigational Site, Markham

N7T 4X3

Novo Nordisk Investigational Site, Sarnia

550 01

Novo Nordisk Investigational Site, Broumov

541 01

Novo Nordisk Investigational Site, Trutnov

00161

Novo Nordisk Investigational Site, Roma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03922750 - A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine | Biotech Hunter | Biotech Hunter